因塞特 INCY 深 滬
等待開盤 09-22 09:30:00 美东时间
86.53
+0.530
+0.62%
華盛通- 最 高86.805
- 今 開85.86
- 成交量 548.38万股
- 最 低 85.3101
- 昨 收 86.00
- 總市值 168.73亿
- 52周最高 87.99
- 市盈率 靜 558.62
- 換手率 2.81%
- 52周最低 53.56
- 委 比 -95.75%
- 總股本 1.95亿
- 歷史最高 153.15
- 量 比 3.38
- 振 幅 1.74%
- 歷史最低 11.76
- 每 手 1
- 風險率 4.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
Analysts' ratings for Incyte (NASDAQ:INCY) over the last quarter vary from bull...
09-20 03:02
22nd Century Group Shares Are Trading Higher Friday: What's Going On?
22nd Century Group shares are trading higher Friday after the company announced it repaid the remaining $3.9 million of its senior unsecured notes.
09-19 23:33
InterCure Enters Premium US Cannabis Market With ISHI Deal
InterCure Ltd. (NASDAQ: INCR) acquires Botanico Ltd., known as ISHI, to strengthen its global cannabis portfolio.
09-19 22:06
Guggenheim Reiterates Neutral on Incyteto Neutral
Guggenheim analyst Michael Schmidt reiterates Incyte (NASDAQ:INCY) from Neutral to Neutral.
09-19 20:43
Incyte Announces Earns FDA Approval For Its Opzelura Cream For Children Ages 2-11 With Atopic Dermatitis
Opzelura is the first topical JAK inhibitor approved in the U.S. for pediatric atopic dermatitis (AD)Phase 3 data supporting the approval show that treatment with Opzelura resulted in significant efficacy, with no new
09-19 04:24
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
ZORYVE, a FDA-approved topical medication for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis, has won the 2025 Allure Best of Beauty Breakthrough Award. It is the first prescription topical drug for these conditions to receive this prestigious honor. ZORYVE offers unique, versatile, and safe solutions for multiple inflammatory skin diseases, providing rapid symptom relief. With cream and foam formulations, it is suitable for all s...
09-16 13:00
Syndax resumed with Buy at Stifel on newly launched drugs
Stifel resumed its coverage of cancer drug developer Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy recommendation and a $44 price target, citing commercial prospects of its newly launched medicines,...
09-11 00:12
美股大行评级 | 潜在涨幅90.8%！Aris Mining获Canaccord Genuity升目标价至17美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Aris Mining"买入"评级，目标价从16.5美元升至17美元；花旗：维持Docusign"买入"评级，目标价从110美元升至115美元
09-05 09:40
B of A Securities Maintains Buy on Incyte, Raises Price Target to $104
B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $90 to $104.
09-05 02:01
22 S&P 500 stocks have lost money over the past decade
Over the past decade, 22 stocks in the S&P 500 have posted negative total returns, according to data compiled by the Bespoke Investment Group, indicating that long-term underperformance is quite rare ...
08-26 17:18
